Warfarin Sodium Tablet
FDA Recall NDC 0093-1721
FDA Enforcement Report: View Recall Date, Reasons, and Safety Status
Active & Historical Enforcement Reports
The FDA has identified 2 recorded enforcement report(s) associated with Warfarin Sodium (NDC 0093-1721). A significant event, classified as Class II, was initiated on Jan 26, 2022 by Teva Pharmaceuticals Usa, Inc.. The reported reason for this action was: "CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions."
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
Reported Recall Events
Class II Terminated
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Jan 26, 2022
Jan 03, 2024
1 unit
Recall Profile & Regulatory Data
Event ID
89450
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
CARDINAL HEALTHCARE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide USA
Termination Date
Sep 29, 2024
Product Description
Warfarin Sodium Tablets, USP, 5 mg, 100 Tablets per bottle, Rx Only, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054. NDC: 0093-1721-01
Batch or Lot Expiration Information
Batch# Batch 2323041
Affected Packages Involved in this Recall
0093-1712-01Product
0093-1712-10Product
0093-1713-01Product
0093-1713-10Product
0093-1714-01Product
0093-1714-10Product
0093-1715-01Product
0093-1716-01Product
0093-1716-10Product
0093-1721-01Product
0093-1721-10Product
0093-1718-01Product
0093-1723-01Product
0093-1720-01Product
Class II Terminated
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Jan 26, 2022
Jan 03, 2024
1 unit
Recall Profile & Regulatory Data
Event ID
89450
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
CARDINAL HEALTHCARE
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide USA
Termination Date
Sep 29, 2024
Product Description
Warfarin Sodium Tablets, USP, 2.5 mg, 100 Tablets per bottle, Rx only, Manufactured For: Teva Pharmaceuticals, Parsippany, NJ 07054. NDC: 0093-1714-01
Batch or Lot Expiration Information
Batch# Batch 2169041
Affected Packages Involved in this Recall
0093-1712-01Product
0093-1712-10Product
0093-1713-01Product
0093-1713-10Product
0093-1714-01Product
0093-1714-10Product
0093-1715-01Product
0093-1716-01Product
0093-1716-10Product
0093-1721-01Product
0093-1721-10Product
0093-1718-01Product
0093-1723-01Product
0093-1720-01Product
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
